Nov 09, 2018 Press Release for Alnylam
Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
Nov 09, 2018
− Givosiran Demonstrated Sustained Clinical Activity, with an Over 90 Percent Decrease in Mean Annualized Porphyria Attack Rate, Relative to Baseline –
− Safety Profile Encouraging with up to 25 Months of Treatment –
“We are encouraged by the sustained clinical activity and safety profile of givosiran in the ongoing Phase 1/2 OLE study, now with up to over two years of dosing. We believe these results demonstrate clinically meaningful reductions in neurotoxic biomarkers, porphyria attack rate, and hemin usage, supporting the potential of givosiran to be an important treatment option for AHP patients,” said Akin Akinc, Vice President and General Manager, Givosiran Program at Alnylam. “We remain committed to bringing givosiran to patients as rapidly as possible, and are on course to initiate a rolling submission for an NDA by the end of 2018, and report topline results from the ENVISION Phase 3 pivotal study in early 2019.”
“Patients with acute hepatic porphyria not only endure potentially
life-threatening neurovisceral attacks but often present with
debilitating chronic symptoms and a severely diminished quality of life,
highlighting the profound unmet need in this disease setting for both
patients and their caregivers,” said
Updated Phase 1/2 OLE Results
As of the data cut-off date of
Serious adverse events (SAEs) were reported in four patients. Previously reported SAEs included: a patient with an upper extremity deep vein thrombosis, assessed as unlikely related to study drug by the investigator; and one patient who had an anaphylactic reaction after the third dose of givosiran, assessed as definitely related to study drug, which resolved with medical management. New SAEs included: a patient with two episodes of pyrexia related to a suspected Port-a-Cath infection and chlamydia bronchitis, assessed as unlikely related to study drug; and one patient with a change in mental status due to a possible glucocorticoid toxicity from an acute bacterial sinusitis, both of which were assessed as unlikely related to study drug. Adverse events (AEs) occurring in three or more patients included abdominal pain, fatigue, injection site erythema, nausea, myalgia, diarrhea, headache, and nasopharyngitis. Six patients had injection site reactions, all mild to moderate. No clinically significant increases in liver function tests or lipase levels were noted with continued dosing in the OLE study.
Results presented at AASLD can be viewed on the Capella section of the Alnylam website.
*Attacks requiring hospitalization, urgent health care visit or hemin administration, which is the attack rate definition used in the ENVISION Phase 3 trial.
About Givosiran Phase 1 Study
The Phase 1 study of givosiran
(Part C) was conducted as a randomized, double-blind, placebo-controlled
study in 17 patients with acute intermittent porphyria (AIP) who
experienced recurrent porphyria attacks. Patients were initially
followed in a 3-month run-in phase, where the number and frequency of
porphyria attacks and levels of ALA and PBG were measured prospectively.
Patients who experienced at least one porphyria attack during the run-in
phase were then eligible to enter the 6-month treatment phase of the
study, where they were randomized to receive 2 once-quarterly doses or 4
once-monthly doses of placebo or givosiran at doses of 2.5 or 5.0 mg/kg.
During the treatment phase, the effects of placebo or givosiran on the
number and frequency of porphyria attacks, as well as on the levels of
ALA and PBG, were measured prospectively in a blinded manner and then
compared to run-in phase results. Additional measures included safety,
tolerability, hospitalizations, use of hemin, levels of ALAS1 mRNA, and
givosiran pharmacokinetics. Hemin is an
About the ENVISION Phase 3 Study
The ENVISION Phase 3 trial
is a randomized, double-blind, placebo-controlled, global, multicenter
study to evaluate the efficacy and safety of givosiran in patients with
a documented diagnosis of an AHP. Patients were randomized on a 1:1
basis to receive 2.5 mg/kg of givosiran or placebo subcutaneously
administered monthly, over a six-month treatment period. The primary
endpoint is the annualized rate of porphyria attacks requiring
hospitalization, urgent healthcare visit or hemin administration at home
over the six-month treatment period. Key secondary and exploratory
endpoints will evaluate reductions in the hallmark symptoms of AHP, such
as pain, nausea, and fatigue, as well as impact on quality of life.
About Acute Hepatic Porphyrias
Acute hepatic porphyrias
(AHPs) are a family of rare, genetic diseases characterized by
potentially life-threatening attacks and for many patients chronic
debilitating symptoms that negatively impact daily functioning and
quality of life. AHPs are comprised of four subtypes, each resulting
from a genetic defect leading to deficiency in one of the enzymes of the
heme biosynthesis pathway in the liver: acute intermittent porphyria
(AIP), hereditary coproporphyria (HCP), variegate porphyria (VP), and
ALAD-deficiency porphyria (ADP). These defects cause the accumulation of
neurotoxic heme intermediates aminolevulinic acid (ALA) and
porphobilinogen (PBG), with ALA believed to be the primary neurotoxic
intermediate responsible for causing both attacks and ongoing symptoms
between attacks. Common symptoms of AHPs include severe, diffuse
abdominal pain, weakness, nausea, and fatigue. Symptoms of AHPs can
often resemble that of other more common conditions such as irritable
bowel syndrome, appendicitis, fibromyalgia, and endometriosis and
consequently, patients afflicted with an AHP are often misdiagnosed or
remain undiagnosed for an average of 15 years. Currently, there are no
treatments approved to prevent debilitating attacks and treat the
chronic symptoms of the disease.
About Givosiran
Givosiran is an investigational,
subcutaneously administered RNAi therapeutic targeting aminolevulinic
acid synthase 1 (ALAS1) in development for the treatment of acute
hepatic porphyria (AHP). Monthly administration of givosiran has the
potential to significantly lower induced liver ALAS1 levels in a
sustained manner and thereby decrease neurotoxic heme intermediates,
aminolevulinic acid (ALA) and porphobilinogen (PBG), to near normal
levels. By reducing accumulation of these intermediates, givosiran has
the potential to prevent or reduce the occurrence of severe and
life-threatening attacks, control chronic symptoms, and decrease the
burden of the disease. Givosiran utilizes Alnylam’s Enhanced
Stabilization Chemistry ESC-GalNAc conjugate technology, which enables
subcutaneous dosing with increased potency and durability and a wide
therapeutic index. Givosiran has been granted Breakthrough Therapy
designation by the
About RNAi
RNAi (RNA interference) is a natural cellular
process of gene silencing that represents one of the most promising and
rapidly advancing frontiers in biology and drug development today. Its
discovery has been heralded as “a major scientific breakthrough that
happens once every decade or so,” and was recognized with the award of
the 2006 Nobel Prize for Physiology or Medicine. By harnessing the
natural biological process of RNAi occurring in our cells, a new class
of medicines, known as RNAi therapeutics, is now a reality. Small
interfering RNA (siRNA), the molecules that mediate RNAi and comprise
Alnylam's RNAi therapeutic platform, function upstream of today’s
medicines by potently silencing messenger RNA (mRNA) – the genetic
precursors – that encode for disease-causing proteins, thus preventing
them from being made. This is a revolutionary approach with the
potential to transform the care of patients with genetic and other
diseases.
About
Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the lives
of people afflicted with rare genetic, cardio-metabolic, hepatic
infectious, and central nervous system (CNS) diseases. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
severe and debilitating diseases. Founded in 2002, Alnylam is delivering
on a bold vision to turn scientific possibility into reality, with a
robust discovery platform. Alnylam’s first U.S.
Alnylam Forward Looking Statements
Various statements in
this release concerning Alnylam's future expectations, plans and
prospects, including, without limitation, Alnylam's views with respect
to the potential benefits of givosiran, plans to initiate a rolling NDA
submission in 2018 and pursue a full approval in 2019 based on the
complete results of the ENVISION Phase 3 study of givosiran, the
expected timing of the report of topline full results from the ENVISION
study, and expectations regarding its “Alnylam 2020” guidance for the
advancement and commercialization of RNAi therapeutics, constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995.
Actual results and future plans may differ materially from those
indicated by these forward-looking statements as a result of various
important risks, uncertainties and other factors, including, without
limitation, Alnylam's ability to discover and develop novel drug
candidates and delivery approaches, successfully demonstrate the
efficacy and safety of its product candidates, the pre-clinical and
clinical results for its product candidates, which may not be replicated
or continue to occur in other subjects or in additional studies or
otherwise support further development of product candidates for a
specified indication or at all, actions or advice of regulatory
agencies, which may affect the design, initiation, timing, continuation
and/or progress of clinical trials or result in the need for additional
pre-clinical and/or clinical testing, delays, interruptions or failures
in the manufacture and supply of its product candidates, obtaining,
maintaining and protecting intellectual property, Alnylam's ability to
enforce its intellectual property rights against third parties and
defend its patent portfolio against challenges from third parties,
obtaining and maintaining regulatory approval, pricing and reimbursement
for products, progress in establishing a commercial and ex-
Givosiran has not been evaluated by the
View source version on businesswire.com: https://www.businesswire.com/news/home/20181109005087/en/
Source:
Alnylam Pharmaceuticals, Inc.
(Investors and Media)
Christine
Regan Lindenboom, 617-682-4340
or
(Investors)
Josh
Brodsky, 617-551-8276
For Media Inquiries, please contact:
Christine Lindenboom
Chief Corporate Communications Officer media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam